Jpmorgan Chase & Co »

Sarepta Therapeutics Inc Note 1.250 9/1 shares owned by Jpmorgan Chase & Co

Quarter-by-quarter ownership of Sarepta Therapeutics Inc Note 1.250 9/1 shares owned by Jpmorgan Chase & Co from 13F filings

Historical chart of Jpmorgan Chase & Co investment in Sarepta Therapeutics Inc Note 1.250 9/1

Tip: Access up to 7 years of quarterly data

All positions including Sarepta Therapeutics Inc Note 1.250 9/1 held by Jpmorgan Chase & Co consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Sarepta Therapeutics Inc Note 1.250 9/1 by Jpmorgan Chase & Co

Quarter filed Position value Share count Share price at filing
2023-12-31 $2.5M 2.5M 1.02
2023-09-30 $4.3M 3.8M 1.12

More positions owned by Jpmorgan Chase & Co

Microsoft Corp Common (MSFT)
Apple Common (AAPL)
Amazon Common (AMZN)
Spdr S&p 500 Etf Trust Fund (SPY)
Nvidia Corporation Common (NVDA)
Meta Platforms Common (META)
Unitedhealth Group Common (UNH)
Vanguard Total Intl Bond Etf Fund (BNDX)
Alphabet Common (GOOG)
Eli Lilly & Co Common (LLY)
Mastercard Incorporated Common (MA)
Alphabet Common (GOOGL)
Abbvie Common (ABBV)
Vanguard Total Bond Market Fund (BND)
Tesla Common (TSLA)

View all positions for Jpmorgan Chase & Co

Top funds holding Sarepta Therapeutics Inc Note 1.250 9/1

Wolverine Asset Management
Calamos Advisors
Braidwell
Highbridge Capital Management
Davidson Kempner Capital Management
Readystate Asset Management
Bank of America Corporation
Lazard Asset Management
Tenor Capital Management
D. E. Shaw & Co
Bank Of Montreal
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Steelhead Partners
Capstone Investment Advisors
Weiss Asset Management LP[1

View all funds holding Sarepta Therapeutics Inc Note 1.250 9/1